Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer
Cutaneous Neuroendocrine Carcinoma
Explore 45 assets in Cutaneous Neuroendocrine Carcinoma →Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Sensei Biotherapeutics, Inc.
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05864144CT.gov A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04916002CT.gov A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer | — | Terminated | — | — | — |
NCT03684785CT.gov Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cutaneous Neuroendocrine Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer (this asset) | Sensei Biotherapeutics, Inc. | P2 | B · 58 |
| Pembrolizumab | Merck Sharp & Dohme LLC | P3 | BB |
| Cyclophosphamide | Merck Sharp & Dohme LLC | P2/3 | BB |
| Fludarabine | Sotio Biotech Inc. | P2 | B |
| Ifx-Hu2.0 | TuHURA Biosciences, Inc. | P2/3 | B |
| Atezolizumab | Ariceum Therapeutics GmbH | P2 | B |
| Nivolumab | Fred Hutchinson Cancer Center | P2 | B |
| Durvalumab | Ariceum Therapeutics GmbH | P2 | B |
| ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE | University of Zurich | P2 | B |
+42 more in the Cutaneous Neuroendocrine Carcinoma cohort
Other indications for Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Skin Squamous Cell Carcinoma | — | P3 | BB · 66 |
| Lung Cancer | — | P2/3 | BB · 65 |
| Nonpapillary Renal Cell Carcinoma | — | P2 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer in Cutaneous Neuroendocrine Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g4-anti-human-programmed-cell-death-protein-1-human-monoclonal-regn2810-heavy-chain-disulfide-with-human-monoclonal-regn2810-kappa-chain-dimer-cutaneous-neuroendocrine-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →